Download MendeleyFusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics.
Jacobs, S.A., Gibbs, A.C., Conk, M., Yi, F., Maguire, D., Kane, C., O'Neil, K.T.(2015) Protein Eng Des Sel 28: 385-393
- PubMed: 26275855 Search on PubMed
- DOI: https://doi.org/10.1093/protein/gzv040
- Primary Citation Related Structures:
2N35 - PubMed Abstract:
A number of classes of proteins have been engineered for high stability using consensus sequence design methods. Here we describe the engineering of a novel albumin binding domain (ABD) three-helix bundle protein. The resulting engineered ABD molecule, called ABDCon, is expressed at high levels in the soluble fraction of Escherichia coli and is highly stable, with a melting temperature of 81.5°C. ABDCon binds human, monkey and mouse serum albumins with affinity as high as 61 pM. The solution structure of ABDCon is consistent with the three-helix bundle design and epitope mapping studies enabled a precise definition of the albumin binding interface. Fusion of a 10 kDa scaffold protein to ABDCon results in a long terminal half-life of 60 h in mice and 182 h in cynomolgus monkeys. To explore the link between albumin affinity and in vivo exposure, mutations were designed at the albumin binding interface of ABDCon yielding variants that span an 11 000-fold range in affinity. The PK properties of five such variants were determined in mice in order to demonstrate the tunable nature of serum half-life, exposure and clearance with variations in albumin binding affinity.
- Janssen Research & Development, L.L.C., 1400 Welsh & McKean Rd., Spring House, Pennsylvania, PA 19454, USA sjacobs9@its.jnj.com.
Organizational Affiliation:
